Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
12:13 MIN
  • CIDP
Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients
DOWNLOAD PDF
Clinical Studies for the Treatment of CIDP with Immunoglobulin
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
9:35 MIN
  • CIDP

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

DOWNLOAD PDF
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
Jeffrey A. Allen, MD
University of Minnesota
12:15 MIN
  • CIDP
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
DOWNLOAD PDF
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
5:24 MIN
  • CIDP

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

DOWNLOAD PDF
NOW PLAYING
12:13
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabiliza...
Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients
NOW PLAYING
9:35
Clinical Studies for the Treatment of CIDP with Immunoglobulin

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

NOW PLAYING
12:15
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
NOW PLAYING
5:24
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

Our Experts on CIDP

Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
  • CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
  • CIDP
  • GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
  • CIDP
  • MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-...
PDF | 3.8 MB
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
PDF | 0.98 MB
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
PDF | 3.4 MB
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
PDF | 680 KB
Back to Top